Cargando…

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective

In the past two decades, extensive efforts have been made to develop agents targeting prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy. To date, represented by two recent approvals of [(68)Ga]Ga-PSMA-11 and [(18)F]F-DCFPyL by the United States Food and Drug Administr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Debnath, Sashi, Zhou, Ning, McLaughlin, Mark, Rice, Samuel, Pillai, Anil K., Hao, Guiyang, Sun, Xiankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835702/ https://www.ncbi.nlm.nih.gov/pubmed/35163083 http://dx.doi.org/10.3390/ijms23031158

Ejemplares similares

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists
por: Debnath, Sashi, et al.
Publicado: (2022)

PSMA Theranostics: Current Landscape and Future Outlook
por: Zhang, Hanbo, et al.
Publicado: (2021)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

The current status of prostate cancer treatment and PSMA theranostics
por: Uemura, Motohide, et al.
Publicado: (2023)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer
por: Gonzalez, Paulina, et al.
Publicado: (2023)

Advances in PSMA theranostics
por: Jeitner, Thomas M., et al.
Publicado: (2022)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
por: Bychkov, Andrey, et al.
Publicado: (2017)

Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives
por: Urso, Luca, et al.
Publicado: (2022)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
por: Flores, Orielyz, et al.
Publicado: (2017)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
por: Seitzer, Konstantin Egon, et al.
Publicado: (2021)

Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective
por: Ng, Thomas S. C., et al.
Publicado: (2021)

The Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer
por: Poot, Alex J., et al.
Publicado: (2020)

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors
por: Lütje, Susanne, et al.
Publicado: (2019)

Regenerative Engineering: Current Applications and Future Perspectives
por: Goldenberg, Dana, et al.
Publicado: (2021)

Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting
por: Lim, Jongdoo, et al.
Publicado: (2019)

Natural Products as Anticancer Agents: Current Status and Future Perspectives
por: Naeem, Abid, et al.
Publicado: (2022)

Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Tumedei, Maria Maddalena, et al.
Publicado: (2021)

Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
por: Schollhammer, Romain, et al.
Publicado: (2023)

Current and future perspectives on functional molecular imaging in nephro-urology: theranostics on the horizon
por: Toyama, Yoshitaka, et al.
Publicado: (2021)

Theranostic Nanomedicines for the Treatment of Cardiovascular and Related Diseases: Current Strategies and Future Perspectives
por: Manners, Natasha, et al.
Publicado: (2022)

Current status of theranostics in prostate cancer
por: Virgolini, Irene, et al.
Publicado: (2017)

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
por: Jang, Albert, et al.
Publicado: (2023)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
por: Fani, Melpomeni, et al.
Publicado: (2017)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers
por: Aide, Nicolas, et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?
por: Lauri, Chiara, et al.
Publicado: (2022)

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives
por: Zschaeck, Sebastian, et al.
Publicado: (2018)

Activatable molecular agents for cancer theranostics
por: Zhang, Jianjian, et al.
Publicado: (2019)

Functionalized Carbon Nanoparticles as Theranostic Agents and Their Future Clinical Utility in Oncology
por: Lee, Seung S., et al.
Publicado: (2023)

Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer
por: Guan, Bing, et al.
Publicado: (2021)

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
por: Lückerath, Katharina, et al.
Publicado: (2018)

Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review
por: Gauthé, Mathieu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4a8j9l3ccarevpj9e8o5l70kut